Original post from Paul Navitsky at Oncolab (www.oncolabinc.com)
(an informational cancer website) posted an article citing an American College of Radiology Imaging Network study that found approximately 58% of women with a high risk of breast cancer agreed to a MRI screen while the remainder refused for a variety of reasons.
Many of the reasons women refused the screening are mitigated by AMAS screening. Primarily, there were issues related directly to the technology behind MRI's, claustrophobia, "medically intolerant to MR imaging", and because of the need for intravenous injection. Yet another reason for women refusing the MRI was financial reasons, the AMAS test is inexpensive when compared to MRI's.
Read the entire article from CancerConsultants.com here:
About the AMAS Cancer test
The AMAS test is a non-invasive screening tool. From a blood sample, a specific antibody (called Anti-Malignin Antibody) can be measured to determine if there is any response from the immune system to several types of cancers in different parts of the body, including breast cancer.
While the test cannot be used to determine the location of the tumor or cancer, it has been proven useful for doctors as a screening and diagnostic tool for over two decades.
Learn more about the AMAS test